Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Colorectal Neoplasms 86Ovarian Neoplasms 33Breast Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Colonic Neoplasms 23Rectal Neoplasms 21Fallopian Tube Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Carcinoma, Hepatocellular 13Glioblastoma 11Lung Neoplasms 10Brain Neoplasms 8Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Intestinal Neoplasms 5Gastrointestinal Neoplasms 5Digestive System Neoplasms 5Brenner Tumor 5Recurrence 4Peritoneal Neoplasms 4Glioma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma of Lung 4Rectal Diseases 3Non-Squamous Non-Small Cell Lung Cancer 3Liver Neoplasms 3Intestinal Diseases 3Gastrointestinal Diseases 3

Interventions

pegfilgrastim 13Filgrastim 8Cyclophosphamide 3liposomal amphotericin B 2eflapegrastim 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Levofloxacin 2Idarubicin 2Fluconazole 2Etoposide 2Docetaxel 2Cytarabine 2Ciprofloxacin 2Cefepime 2Caspofungin 2Amsacrine 2pegylated granulocyte colony-stimulating factor 1ceftobiprole medocaril 1Vancomycin 1Tretinoin 1Thioguanine 1Radiotherapy 1Psychiatric Rehabilitation 1MYL-1401H 1Lithium Carbonate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Daunorubicin 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neutropenia × Bevacizumab × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡